Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis
- PMID: 24459196
- DOI: 10.1093/eurheartj/eht570
Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis
Abstract
Background: The aim of this study was to compare the safety and efficacy of biodegradable-polymer (BP) drug-eluting stents (DES), bare metal stents (BMS), and durable-polymer DES in patients undergoing coronary revascularization, we performed a systematic review and network meta-analysis using a Bayesian framework.
Methods and results: Study stents included BMS, paclitaxel-eluting (PES), sirolimus-eluting (SES), endeavor zotarolimus-eluting (ZES-E), cobalt-chromium everolimus-eluting (CoCr-EES), platinium-chromium everolimus-eluting (PtCr-EES), resolute zotarolimus-eluting (ZES-R), and BP biolimus-eluting stents (BP-BES). After a systematic electronic search, 113 trials with 90 584 patients were selected. The principal endpoint was definite or probable stent thrombosis (ST) defined according to the Academic Research Consortium within 1 year.
Results: Biodegradable polymer-biolimus-eluting stents [OR, 0.56; 95% credible interval (CrI), 0.33-0.90], SES (OR, 0.53; 95% CrI, 0.38-0.73), CoCr-EES (OR, 0.34; 95% CrI, 0.23-0.52), and PtCr-EES (OR, 0.31; 95% CrI, 0.10-0.90) were all superior to BMS in terms of definite or probable ST within 1 year. Cobalt-chromium everolimus-eluting stents demonstrated the lowest risk of ST of all stents at all times after stent implantation. Biodegradable polymer-biolimus-eluting stents was associated with a higher risk of definite or probable ST than CoCr-EES (OR, 1.72; 95% CrI, 1.04-2.98). All DES reduced the need for repeat revascularization, and all but PES reduced the risk of myocardial infarction compared with BMS.
Conclusions: All DESs but PES and ZES-E were superior to BMS in terms of ST within 1 year. Cobalt-chromium everolimus-eluting stents was safer than any DES even including BP-BES. Our results suggest that not only the biodegradability of polymer, but the optimal combination of stent alloy, design, strut thickness, polymer, and drug all combined determine the safety of DES.
Keywords: Bare metal stents; Biodegradable polymer drug-eluting stents; Drug-eluting stents; Meta-analysis.
Comment in
-
Drug-eluting stents with biodegradable polymers: are enough data in for a final assessment?Eur Heart J. 2014 May;35(17):1098-100. doi: 10.1093/eurheartj/ehu037. Epub 2014 Feb 16. Eur Heart J. 2014. PMID: 24536082 No abstract available.
Similar articles
-
Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.J Am Coll Cardiol. 2014 Feb 4;63(4):299-307. doi: 10.1016/j.jacc.2013.09.061. Epub 2013 Nov 6. J Am Coll Cardiol. 2014. PMID: 24211507 Review.
-
Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials.JACC Cardiovasc Interv. 2016 Jun 27;9(12):1203-1212. doi: 10.1016/j.jcin.2016.03.038. Epub 2016 Jun 1. JACC Cardiovasc Interv. 2016. PMID: 27262860
-
Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis.J Am Coll Cardiol. 2013 Aug 6;62(6):496-504. doi: 10.1016/j.jacc.2013.05.022. Epub 2013 Jun 7. J Am Coll Cardiol. 2013. PMID: 23747778
-
Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis.BMJ. 2013 Nov 6;347:f6530. doi: 10.1136/bmj.f6530. BMJ. 2013. PMID: 24196498 Free PMC article.
-
Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis.J Am Coll Cardiol. 2015 Jun 16;65(23):2496-507. doi: 10.1016/j.jacc.2015.04.017. J Am Coll Cardiol. 2015. PMID: 26065988
Cited by
-
Comparison of long-term clinical outcomes of bioabsorbable polymer versus durable polymer drug-eluting stents: a systematic review and meta-analysis.Egypt Heart J. 2024 Jul 10;76(1):91. doi: 10.1186/s43044-024-00522-1. Egypt Heart J. 2024. PMID: 38985375 Free PMC article. Review.
-
Risk of discontinuation of clopidogrel after 1 month following bare-metal stents: a propensity-score adjusted comparison with continued administration of clopidogrel after drug-eluting stents.J Thromb Thrombolysis. 2018 Apr;45(3):432-439. doi: 10.1007/s11239-018-1613-6. J Thromb Thrombolysis. 2018. PMID: 29349545 Clinical Trial.
-
A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary artery lesions: The SPIRIT WOMEN study.PLoS One. 2017 Aug 10;12(8):e0182632. doi: 10.1371/journal.pone.0182632. eCollection 2017. PLoS One. 2017. PMID: 28796809 Free PMC article. Clinical Trial.
-
Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial.Eur Heart J Cardiovasc Imaging. 2016 Jan;17(1):34-40. doi: 10.1093/ehjci/jev203. Epub 2015 Sep 1. Eur Heart J Cardiovasc Imaging. 2016. PMID: 26333375 Free PMC article. Clinical Trial.
-
Two-year clinical outcomes of zotarolimus- and everolimus-eluting durable-polymer-coated stents versus biolimus-eluting biodegradable-polymer-coated stent in patients with acute myocardial infarction with dyslipidemia after percutaneous coronary intervention: data from the KAMIR.Heart Vessels. 2019 Feb;34(2):237-250. doi: 10.1007/s00380-018-1251-0. Epub 2018 Aug 30. Heart Vessels. 2019. PMID: 30167772
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical